HistoSonics announced the first use of its Vortx RX device to treat a patient with Benign Prostatic Hyperplasia in a pilot clinical trial at the University of Michigan's department of urology.
The Vortx RX is an investigational device and is based on histotripsy technology — a non-thermal focused ultrasound therapy that mechanically liquefies targeted tissues.
Urologist John Wei, MD, performed the first Vortx RX treatment at the university.
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products
The Vortx RX is an investigational device and is based on histotripsy technology — a non-thermal focused ultrasound therapy that mechanically liquefies targeted tissues.
Urologist John Wei, MD, performed the first Vortx RX treatment at the university.
More Articles on Supply Chain:
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products